FDA Orange Book · active-ingredient family
Lusutrombopag
Lusutrombopag is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:MULPLETA · NDA 210923
1
Brand (NDA)
0
Generics (ANDA)
3
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| MULPLETARLD | VANCOCIN ITALIA | NDA 210923 | — | Jul 31, 2018 |
Listed patents (3)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8889722 | Jul 29, 2028 | in 2 yr 2 mo | SubstanceProduct |
| 8530668 | Jan 21, 2030 | in 3 yr 8 mo | SubstanceProduct |
| 9427402 | Sep 29, 2031 | in 5 yr 4 mo | Product |
Lusutrombopag — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
